AI
Trump AI Order Cuts Testing Window to 30 Days
Trump's AI order cuts pre-release review to 30 days, makes testing voluntary, and lets AI firms decide which of their own models get scrutinized.
Latest — Page 13
Legal
Filed: NFHA, SolasAI Sue CFPB Over ECOA Rollback
Four plaintiffs including AI bias-detection firm SolasAI sued CFPB in D.C. to block the April rule stripping disparate impact from ECOA.
FDA
Paid $1.2B for IBI363, Takeda Gets 47% 2-Year Survival
IBI363's phase 1 data put 47% of IO-resistant NSCLC patients alive at 24 months, the first real test of Takeda's $11.4B Innovent bet.
Legal
Exploited Palo Alto Flaw Flips to Critical
A PAN-OS authentication bypass rated medium on May 13 is now critical and actively exploited, with federal agencies ordered to patch by June 19.
Deals
Alphabet Raises $80B; Berkshire Buys $10B Stake
Alphabet's $80B equity raise, anchored by Berkshire's $10B, signals the moment AI capex outpaces Big Tech's collective ability to self-fund.
Legal
EU Bars Amazon, Google, Microsoft From Cloud Bids
EU's Cloud and AI Development Act mandates EU-built software in public tenders, a direct shot at Amazon, Google, and Microsoft's state contracts.
Deals
Paid £15B in Year One, Amazon Ahead on £40B UK Pledge
Amazon hit £15 billion of a £40 billion UK pledge in year one, ahead of pace, while embedding a new payment into Prime's billing chain.
Legal
Delayed Again: Illinois IFPA Pushed to 2027
Illinois legislators delayed the IFPA swipe fee ban a second year in a row, but OCC preemption means the 2027 date may mean little for national banks.
AI
Filed 1,400 Pixel Suits as 63% of AI Vendors Skip Disclosure
63.6% of AI vendors don't disclose their subprocessors, 145 state laws hit in 2025, and your CEO now faces personal perjury risk by April 2028.
Deals
Lilly Paid $1.26B to License Hanmi's GLP-2
Lilly's $75M upfront bet on Hanmi's once-monthly GLP-2 could reach $1.26B if sonefpeglutide survives FDA, and its main rival already stumbled.
FDA
Akeso Ivonescimab Cuts Death Risk 34% in Squamous NSCLC
Ivonescimab posted HR 0.66 and a four-month survival edge in HARMONi-6; Summit now needs its global HARMONi-3 data to deliver the same.
Legal
OMB Files Grant Rule: Agencies Cancel at Any Time
OMB's proposed rule hands political appointees full grant veto power, bans DEI and gender research, and lets agencies cancel awards at will.
FDA
Cuts Metastasis Risk 20%: J&J's Erleada Targets Surgery
J&J's Proteus phase 3 shows Erleada cut metastasis risk 20% and nearly doubled time before additional therapy, from 3.5 to 6-plus years.
FDA
Ivonescimab Cuts NSCLC Death Risk 34% in Phase 3
Ivonescimab's 34% OS win over PD-1 chemo in squamous NSCLC is a phase 3 first, but the trial excluded patients over 75 and enrolled almost no women.
Deals
Lilly Paid $3.2B for Kelonia's 100% CAR-T Response
Lilly's $3.2B upfront bet on Kelonia just got its first real validation: 18 of 18 myeloma patients hit MRD-negative status at one month.
